1.Обзори / Политики

1.1. Are the European reference networks for rare diseases ready to embrace machine learning? A mixed-methods study.
Iskrov G, Raycheva R, Kostadinov K, Gillner S, Blankart CR, Gross ES, Gumus G, Mitova E, Stefanov S, Stefanov G, Stefanov R.
Orphanet J Rare Dis. 2024 Jan 25;19(1):25. doi: 10.1186/s13023-024-03047-7.
PMID: 38273306
Impact factor: 3.7

1.2. Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review.
Raycheva R, Kostadinov K, Mitova E, Bogoeva N, Iskrov G, Stefanov G, Stefanov R.
Front Public Health. 2023 Sep 15;11:1214766. doi: 10.3389/fpubh.2023.1214766. eCollection 2023.
PMID: 37780450
Impact factor: 5.2

1.3. What is the awareness of rare diseases among medical students? A survey in Bulgaria.
Hristova-Atanasova E, Iskrov G, Atanasov I, Genc A, Stefanov R.
Orphanet J Rare Dis. 2023 Jul 25;18(1):213. doi: 10.1186/s13023-023-02820-4.
PMID: 37491304
Impact factor: 3.7

1.4. Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria.
Ignatova V, Kostadinov K, Vassileva E, Muradyan N, Stefanov G, Iskrov G, Stefanov R.
Front Public Health. 2022 Mar 3;10:822909. doi: 10.3389/fpubh.2022.822909. eCollection 2022.
PMID: 35309194
Impact factor: 5.2

1.5. Health systems for rare diseases: financial sustainability.
Iskrov G, Stefanov R, Ferrelli RM.
Ann Ist Super Sanita. 2019 Jul-Sep;55(3):270-275. doi: 10.4415/ANN_19_03_13.
PMID: 31553322
Impact factor: 1.3

1.6. Schooling of children with rare diseases and disability in Europe
R Linertová, J González-Guadarrama, P Serrano-Aguilar,
International Journal of Disability, Development and Education 66 (4), 362-373; https://doi.org/10.1080/1034912X.2018.1562159
Impact factor: 0.7

1.7. Access to orphan drugs – comparison across Balkan countries.
Pejcic AV, Iskrov G, Jakovljevic MM, Stefanov R.
Health Policy. 2018 Jun;122(6):583-589. doi: 10.1016/j.healthpol.2018.04.009. Epub 2018 Apr 26.
PMID: 29729905
Impact factor: 2.1

1.8 International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases.
Am J Hum Genet. 2017 May 4;100(5):695-705. doi: 10.1016/j.ajhg.2017.04.003.
PMID: 28475856
Impact factor: 8.9

1.9. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ 17 (Suppl 1), 19–29 (2016). Cavazza, M., Kodra, Y., Armeni, P. et al; https://doi.org/10.1007/s10198-016-0782-5
Impact factor: 2.5

1.10. Transposition and implementation of EU rare disease policy in Eastern Europe.
Pejcic AV, Iskrov G, Raycheva R, Stefanov R et al.
Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):557-566. doi: 10.1080/14737167.2017.1388741. Epub 2017 Oct 10.
PMID: 28975845
Impact factor: 1.8

1.11. Информираност за редките болести сред студентите-медици в Пловдив
E Христова, И Aтанасов, Й Дончева, С Стефанов, A Иванова, Conference Proceedings, 170-170

1.12. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.
Chevreul K, Michel M, Brigham KB et.al.
Eur J Health Econ 17 (Suppl 1), 7–18 (2016).https://doi.org/10.1007/s10198-016-0781-6,
PMID: 27059622
Impact factor: 2.5

1.13. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.
Iskrov G, Astigarraga I, Stefanov R,et al.;
Eur J Health Econ. 2016 Apr;17 Suppl 1:67-78. doi: 10.1007/s10198-016-0790-5. Epub 2016 Apr 4.
PMID: 27042831
Impact factor: 2.5

1.14. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.
Angelis A, Kanavos P, López-Bastida J, et al.
BMC Musculoskelet Disord. 2016 Aug 2;17:321. doi: 10.1186/s12891-016-1129-1.
PMID: 27484740
Impact factor: 1.7

1.15. Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe.
Péntek M, Gulácsi L, Brodszky V, Baji P, et al.
c. 2016 Apr;17 Suppl 1:89-98. doi: 10.1007/s10198-016-0787-0. Epub 2016 Apr 9.
PMID: 27062257
Impact factor: 2.5

1.16. Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.
Angelis A, Kanavos P, López-Bastida J. et al.
Eur J Health Econ. 2016 Apr;17 Suppl 1(Suppl 1):31-42. doi: 10.1007/s10198-016-0783-4. Epub 2016 Apr 23.
PMID: 27107597
Impact factor: 2.5

1.17. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.
López-Bastida J, Linertová R, Oliva-Moreno J, et al.
Eur J Health Econ. 2016 Apr;17 Suppl 1:99-108. doi: 10.1007/s10198-016-0788-z. Epub 2016 Apr 2.
PMID: 27038627
Impact factor: 2.5

1.18. Overview of epidemiological registries in Bulgaria
T Miteva-Katrandzhieva, G Iskrov, R Stefanov, E Naumova, Rare Dis Orphan Drugs 3 (1), 11-15

1.19. National registries of rare diseases in Europe: an overview of the current situation and experiences.
Taruscio, D., Vittozzi, L., Choquet, R., Heimdal, K., Iskrov, G., Kodra, Y., Landais, P., Posada, M., Stefanov, R., Steinmueller, C., Swinnen, E., & Van Oyen, H.
Public Health Genomics. 2015;18(1):20-5. doi: 10.1159/000365897. Epub 2014 Sep 9.
PMID: 25228300
Impact factor: 1.5

1.20. National Plans on Rare Diseases.
Taruscio, D. et al. (2015). In: Özgüç, M. (eds)
Rare Diseases. Advances in Predictive Preventive and Personalised Medicine, c vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9214-1_1

1.21. Expertise centers and national registry for rare diseases in Bulgaria – perspectives and challenges.
Iskrov,G., Hristova,E., Stefanov,R.,
Obsha Meditsina / General Medicine, 2015, Vol. 17, No. 2, 3-8, Medical University Sofia – Central Medical Library, Bulgaria

1.22. Достъп до иновативни лекарствени терапии чрез споделяне на риска
Г Искров, Р Стефанов. Здравна политика и мениджмънт. 2015;15(1):20-7.

1.23. The economic burden and health-related quality of life associated with systemic sclerosis in France.
Chevreul K, Brigham KB, Gandré C, Mouthon L;
Scand J Rheumatol. 2015 May;44(3):238-46. doi: 10.3109/03009742.2014.976653. Epub 2014 Dec 18.
PMID: 25521915
Impact factor: 2.5

1.24. Economic Burden And Health-Related Quality Of Life Of Patients With Cystic Fibrosis In Bulgaria.
Iskrov GG, Stefanov RS, López-Bastida Jet al.
Folia Med (Plovdiv). 2015 Jan-Mar;57(1):56-64. doi: 10.1515/folmed-2015-0020.
PMID: 26431096

1.25. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
Angelis A, Kanavos P, López-Bastida J, et al.
BMC Health Serv Res. 2015 Sep 28;15:428. doi: 10.1186/s12913-015-1061-3.
PMID: 26416027
Impact factor: 1.6

1.26. Epidemiological registry of neuroendocrine tumors in Bulgaria – a pilot survey.
Stefanov R, Miteva-Katrandjieva Ts, Iskrov G, et al.
Khirurgiia (Sofia). 2014; 80 (4):7-13.

1.27. Праг за разходна ефективност при реимбурсните решения – теоретична концепция и практически предизвикателства за България.
Г Искров, Р Стефанов.
Здравна икономика и мениджмънт 53 (3), 11-16, 2014

1.28. Methodology for production of best practice guidelines for rare diseases
T Sejersen, C Del Giovane, G Filippini, et al.
Rare Diseases and Orphan Drugs 1 (1), 2014

1.29. RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases.
D Taruscio, C Morciano, P Laricchiuta, et al.
Orphanet J Rare Dis 9 (Suppl 1), O14 (2014).
Impact factor: 3.4

1.30. A comprehensive analysis of access to orphan drugs in Bulgaria, budget impact of medicinal therapies for rare diseases and good practices for rare disease patient access to orphan drugs in the EU. Centre for Analyses and Health Technology Assessment
G Iskrov, R Stefanov – Institute for Rare Diseases, 2014

1.31. EUROPLAN: A Project to Support the Development of National Plans on Rare Diseases in Europe.
Taruscio D, Gentile AE, De Santis M, et al.
Public Health Genomics. 2013;16 (6):278-87.
doi: 10.1159/000355932
Impact factor: 2.5

1.32. Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study.
Linertová R, Serrano-Aguilar P, Posada-de-la-Paz Met al.
Health Policy. 2012 Nov;108(1):19-26.
PMID: 22947412
doi: 10.1016/j.healthpol.2012.08.001
Impact factor: 1.6

1.33. Редките болести и лекарствата сираци в България – предизвикателства и приоритети за действие.
Искров Г, Ц. Митева-Катранджиева, Р. Стефанов.
Педиатрия 2012, 52 (1 SUPPL.): 55-57.

1.34. Перспективи за създаване на експертни центрове по редки болести в България.
Симеонова Р, Искров Г, Стефанов Р.
Педиатрия 2012, 52 (1 SUPPL.): 58-61

1.35. General knowledge and awareness on rare diseases among general practitioners in Bulgaria.
Miteva Ts, Jordanova R, Iskrov G, Stefanov R.
Georgian Medical News. 2011 Apr(193):16-19.
PMID: 21617267.

1.36. National plans and strategies on rare diseases in Europe.
Taruscio D, Vittozzi L, Stefanov R.
Adv Exp Med Biol. 2010;686:475-91. doi: 10.1007/978-90-481-9485-8_26.
PMID: 20824461
Impact factor: 1.4

1.37. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.
Bresin E, Daina E, Noris M, et al.
Clin J Am Soc Nephrol. 2006 ;1(1):88-99.
doi:10.2215/CJN.00050505

1.38. Tackling rare diseases at European level: why do we need a harmonized framework?
Taruscio D, Trama A, Stefanov R.
Folia Med (Plovdiv). 2007; 49(1-2):59-67.
PMID: 18018471;

1.39. Quality of life in patients with unusual diseases: experience of nurses at the clinical research center for unusual diseases
Aldo e Cele Daccò. Gamba S, Cicci L, Stefanov R.
Assist Inferm Ric. 2003 Jul-Sep;22(3):144-50.
PMID: 14666852 ;

1.40 Landscape analysis of available European data sources amenable for machine learning and recommendations on usability for rare diseases screening.
Raycheva R, Kostadinov K, Mitova E, Iskrov G, Stefanov G, Vakevainen M, et al. Orphanet Journal of Rare Diseases. 2024 Apr 6;19(1).
doi: 10.1186/s13023-024-03162-5
Impact factor: 3.4

2.  Достъп до лечение / Оценката на здравните технологии 

2.1. Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel.
Ben-Aharon O, Sergienko R, Iskrov G, Greenberg D.
Isr J Health Policy Res. 2024 Feb 19;
13(1):9. doi: 10.1186/s13584-024-00594-z.
PMID: 38374060
Impact factor: 4.1

2.2. Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape. Kostadinov K, Marinova Y, Dimitrov K, Hristova-Atanasova E, Iskrov G, Stefanov R.
InHealthcare 2024 Feb 11 (Vol. 12, No. 4, p. 458). MDPI.
https://doi.org/10.3390/healthcare12040458
Impact factor: 3.0

2.3. Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review. Ben-Aharon O, Iskrov G, Sagy I, Greenberg D.
Expert Rev Pharmacoecon Outcomes Res. 2023 Mar;23(3):281-295. doi: 10.1080/14737167.2023.2167713. Epub 2023 Jan 24.
PMID: 36635646
Impact factor: 2.3

2.4. HTA7 The Price of Innovation–Oncology Treatments Expenditures: Case from Bulgaria
R Raycheva, K Kostadinov,
Value in Health 26 (6), S260, June 2023
https://doi.org/10.1016/j.jval.2023.03.1436
Impact factor: 4.5

2.5. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward.
R Baltussen, K Marsh, P Thokala, et al. Value in Health 22 (11), 2019, 1283-1288. https://doi.org/10.1016/j.jval.2019.06.014.
Impact factor: 4.7

2.6. HTA69 Delay of Innovative Oncology Treatments-Case From Bulgaria
R Raycheva, K Kostadinov,
Value in Health 25 (12), S309-S310, Dec. 2022
https://doi.org/10.1016/j.jval.2022.09.1529
Impact factor: 4.5

2.7. PCN263 ONCOLOGY DRUGS-INNOVATION ON HIGH SPEED
R Raycheva, Value in Health 23, S69, May 2020
https://doi.org/10.1016/j.jval.2020.04.1730
Impact factor: 5.7

2.8. What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria.
Iskrov G, Greenberg D, Yakimov I, Cholakova H, Stefanov R. Value Health Reg Issues. 2019 Sep;19:157-162. doi: 10.1016/j.vhri.2019.03.005. Epub 2019 May 17.
PMID: 31109901
Impact factor: 4.7

2.9. What could gene therapies learn from orphan drugs’ post-regulatory approval access in the EU?
G Iskrov, G Vasilev, R Stefanov; Expert Opinion on Orphan Drugs 7 (9), 407-414
Expert Opinion on Orphan Drugs, 7:9, 407-414, Sep.2019;
DOI: 10.1080/21678707.2019.1663171
Impact factor: 3.4

2.10. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies:
Benefits, Limitations, and the Way Forward.
Baltussen R, Marsh K, Thokala P, et al. Value Health. 2019 Nov;22(11):1283-1288. doi: 10.1016/j.jval.2019.06.014.
PMID: 31708065
Impact factor: 4.7

2.11. PP55 HTA And High Cost Innovative Therapies-Focus On Cancer Drugs.
R Raycheva, R Stefanov.
International Journal of Technology Assessment in Health Care. 2018; 34 (S1), 88-88
Impact factor: 1.4

2.12. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria.
Iskrov GG, Jakovljevic MM, Stefanov RS.
Folia Med (Plovdiv). 2018 Mar 1;60(1):79-91.
PMID: 29668449;
doi: 10.2478/folmed-2018-0015

2.13. PP071 Health Technology Assessment In Bulgaria: A Review Of The First Fifteen Reports Assessed.
R Raycheva, G Iskrov, R Stefanov.
International Journal of Technology Assessment in Health Care , Volume 33, Special Issue S1, 2017, 103 – 104
DOI: https://doi.org/10.1017/S0266462317002458
Impact factor: 1.3

2.14. VP94 Framework Of High-Quality Value Assessment Criteria In Health Care.
R Raycheva, R Stefanov.
International Journal of Technology Assessment in Health Care 33 (S1), 2017, 191-192
DOI: https://doi.org/10.1017/S0266462317003580
Impact factor: 1.3

2.15. VP81 Health Technology Assessment And Rare Disease Decision Making: Focus On Orphan Drugs. R Raycheva, R Stefanov
International Journal of Technology Assessment in Health Care 33 (S1), 2017, 186-187
DOI: https://doi.org/10.1017/S0266462317003518
Impact factor: 1.3

2.16. Health Technology Assessment and Appraisal of Therapies for Rare Diseases.
Iskrov G, Miteva-Katrandzhieva T, Stefanov R.
Adv Exp Med Biol. 2017;1031:221-231. PMID: 29214575
doi: 10.1007/978-3-319-67144-4_13
Impact factor: 1.8

2.17. Expenditure trends of orphan drugs in Serbia: 8-year analysis of orphan drug market in Serbia.
AV Pejčić, GG Iskrov.
Hospital Pharmacology, 2016, 3 (3), 422-434
doi:10.5937/hpimj1603422P

2.18. Incorporation of Multi-Criteria Decision Analysis into Health Technology Assessment: Experiences and Challenges from Bulgaria.
G Iskrov, R Kuncheva, R Stefanov.
Health Economics and Policy Challenges in Global Emerging Markets. 2016: 41-58

2.19. Ensuring Transparency and Consistency in the Value Assessment of Cancer Therapies.
G Iskrov, R Stefanov. Journal of Clinical Oncology,Vol.34, N 24, 2016
https://doi.org/10.1200/JCO.2015.63.6076
Impact factor: 24.0

2.20. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
Iskrov G, Miteva-Katrandzhieva T, Stefanov R.
Front Public Health. 2016 Sep 30;4:214.PMID: 27747207
doi: 10.3389/fpubh.2016.00214
Impact factor: 1.8

2.21.Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion.
Iskrov G, Dermendzhiev S, Miteva-Katrandzhieva T, Stefanov R.
Front Pharmacol. 2016 Aug 17;7:252. PMID: 27582707
doi: 10.3389/fphar.2016.00252
Impact factor: 2.3

2.22. Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.
Chevreul K, Gandré C, Brigham KB et al.
Eur J Health Econ. 2016 Apr;17 Suppl 1:43-52. PMID: 27072054
doi: 10.1007/s10198-016-0784-3
Impact factor: 2.5

2.23. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Cavazza M, Kodra Y, Armeni P, et al. Eur J Health Econ. 2016 Apr;17 Suppl 1:19-29. PMID: 27038625
doi: 10.1007/s10198-016-0782-5
Impact factor: 2.5

2.24. Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.
Iskrov G, Stefanov R.
Balkan Med J. 2016 Jan;33(1):27-35. PMID: 26966615
doi: 10.5152/balkanmedj.2015.15185
Impact factor: 1.1

2.25. Stakeholders involvment in HTA activities: multifaceted profile, motives and incentives,
Raycheva R,
International Journal Scientific and applicative papers V10/1, 2015
Impact factor: 3.2

2.26. Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in Bulgaria.
Iskrov G, Stefanov R.
Front Public Health. 2015 Apr 22;3:64.
doi: 10.3389/fpubh.2015.00064
PMID: 25954739.
Impact factor: 2.0

2.27. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
G Iskrov, E Jessop, T Miteva-Katrandzhieva, R Stefanov.
Georgian Med News. 2015; (242):46-53.

2.28. Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations.
G Iskrov, R Stefanov.
Orphan Drugs: Research and Reviews 2014, 4:1-9.
DOI https://doi.org/10.2147/ODRR.S43409

2.29. Оценка на иновативни здравни технологии за онкологични и редки заболявания.
Г Искров, Р Стефанов. Наука Фармакология 2014, 5 (2), 13-19

2.30. European Network of Rare Disease Help Lines (ENRDHLs)–caller profile analysis 2013
G Iskrov, F Houÿez.
Orphanet J Rare Dis 9 (Suppl 1), O13 (2014) https://doi.org/10.1186/1750-1172-9-S1-O13
Impact factor: 3.4

2.31. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
Iskrov GG, Raycheva RD, Stefanov RS.
Folia Med (Plovdiv). 2013 Jul-Dec;55(3-4):80-6. PMID: 24712287
doi: 10.2478/folmed-2013-0032

2.32. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G, Miteva-Katrandzhieva T, Stefanov R.
Health Policy. 2012 Nov;108 (1):10-8.
PMID: 22939047
doi: 10.1016/j.healthpol.2012.08.013
Impact factor: 1.5

3. Неонатален скрининг

3.1. Rare diseases’ genetic newborn screening as the gateway to future genomic medicine: the Screen4Care EU-IMI project. Ferlini A, Gross ES, Garnier N; Screen4Care consortium.
Orphanet J Rare Dis. 2023 Oct 4;18(1):310. PMID: 37794437
doi: 10.1186/s13023-023-02916-x
Impact factor: 3.7

3.2. Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe.
PLoS One. 2023 Nov 22;18(11):e0293503.
PMID: 37992053
doi: 10.1371/journal.pone.0293503
Impact factor: 3.7

3.3. Prospects for Expansion of Universal Newborn Screening in Bulgaria: A Survey among Medical Professionals.
Int J Neonatal Screen. 2023 Oct 11;9(4):57.
PMID: 37873848.
doi: 10.3390/ijns9040057
Impact factor: 3.5

3.4.Autistic Adult Services Availability, Preferences, and User Experiences: Results From the Autism Spectrum Disorder in the European Union Survey.
Front Psychiatry. 2022 Jun 10;13:919234.
PMID: 35757227. doi: 10.3389/fpsyt.2022.919234
Impact factor: 3.8

3.5. Real-World Experiences in Autistic Adult Diagnostic Services and Post-diagnostic Support and Alignment with Services Guidelines: Results from the ASDEU Study.
J Autism Dev Disord. 2021 Nov;51(11):4129-4146.
PMID: 33502713.
doi: 10.1007/s10803-021-04873-5
Impact factor: 4.3

3.6. Practice Patterns for Early Screening and Evaluation for Autism Spectrum Disorder Diagnosis in Bulgaria.
Iskrov G, Vasilev G, Mitev M, Nikolova R, Stoykova M, Stefanov R.
J Autism Dev Disord. 2021 Mar;51(3):778-789.
PMID: 31414261.
doi: 10.1007/s10803-019-04170-2
Impact factor: 4.3

3.7. Pan-european landscape of research into neurodevelopmental copy number variants: A survey by the MINDDS consortium.
Eur J Med Genet. 2020 Dec;63(12):104093.
PMID: 33160096.
doi: 10.1016/j.ejmg.2020.104093
Impact factor: 2.7

3.8. Whole-Genome Sequencing in Newborn Screening-Attitudes and Opinions of Bulgarian Pediatricians and Geneticists. Iskrov G, Ivanov S, Wrenn S, Stefanov R.
Front Public Health. 2017 Nov 20;5:308.
PMID: 29250518.
doi: 10.3389/fpubh.2017.00308
Impact factor: 1.7

3.9. Interobserver agreement in diagnosing liver involvement in hereditary hemorrhagic telangiectasia by Doppler ultrasound.
Buscarini E, Gebel M, Ocran K, Manfredi G, Del Vecchio Blanco G, Stefanov R, et al. Ultrasound Med Biol. 2008 May;34(5):718-25.
PMID: 18207308.
doi: 10.1016/j.ultrasmedbio.2007.11.007

3.10. Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model.
Dimitrov BD, Ruggenenti P, Stefanov R, Perna A, Remuzzi G. Nephron Clin Pract. 2003;95(2):c47-59. PMID: 14610330.
doi: 10.1159/000073668

3.11 The modernisation of newborn screening as a pan-European challenge – An international delphi study
Gillner S, Gumus G, Gross E, Iskrov G, Raycheva R, Stefanov G, et al. Health Policy. 2024 Sep 13;149:105162.
doi: 10.1016/j.healthpol.2024.105162
Impact factor: 3.6